







BALAGANI PAVAN KUMARa*, PALLEPATI KAVITHAb, KATAMREDDY JYOTHSHNA DEVIa 
a* Department of Pharmaceutics, Gokula Krishna College of Pharmacy, Sullurpet-524121, A.P, India, b
 Received: 10 Apr 2014 Revised and Accepted: 15 May 2014 
Department of Pharmaceutics,Gokula 
Krishna College of Pharmacy, Sullurpet-524121, A.P, India. 
Email: pavan.gkcp@rediffmail.com 
ABSTRACT 
Objective: The main objective of present investigation is to prolong drug action and enhance bioavailability.  
Methods: The tablets were prepared using Carbopol 934 in varying concentration with secondary polymers like HPMC K4M, HPMC K15M and 
sodium alginate by direct compression method. The compatibility studies like TLC and FTIR spectroscopy were carried out. The tablets were 
evaluated for hardness, thickness, weight variation, friability and drug content and concluded that all these parameters were in acceptable range of 
pharmacopoeial specification. The tablets were furtherevaluated for their mucoadhesive characteristics such as surface pH, swelling index, ex vivo 
residence time, mucoadhesive strength, ex vivo permeation,in vitro drug release and also for the effect of Carbopol concentration on mucoadhesive 
parameters.  
Results: The surface pH of the tablet was 6.48 to 6.75 which fall in the range of salivary pH and all the tablet of batch C containing sodium alginate 
as secondary polymer showed ex vivo residence time of 10 to 12.30 hrs indicated good mucoadhesive capacity of tablet. The buccal tablets showed 
good swelling up to 8 hrs maintaining the integrity of polymers. The formulation (C3) showed better control of drug release and able to release 
entire amount of drug in 12 hrs than the other formulations. All the formulations of batch C & A except A1 followed zero order kinetics and all other 
formulations of batch B and A1 formulation followed Hixson-Crowell model.The ‘n’ value of all the formulations was found to be more than 0.89 
indicating that the drug release followed Super case II transport type of release mechanism due to the erosion of the polymer. All the tablets showed 
good mucoadhesive strength in the range of 21.87 to 26.26.Ex vivopermeation studies of the optimized formulation C3 revealed that percent drug 
permeated through sheep buccal mucosa was 38.294 % for 8 hrs. The slopes of the basic in vitro data suggests that drug permeates across the 
membrane but slowly as the mucosa offers barrier to the transportation of the drug.  
Conclusion: Hence Carbopol 934 and Sodium alginate polymers can be used to prepare mucoadhesive buccal tablets of nitroglycerin having 
prolonged therapeutic effect with enhanced bioavailability.  
Keywords: Nitroglycerin, Swelling index, In vitro drug release. Mucoadhesion, Ex vivo permeation. 
 
INTRODUCTION 
Buccal drug delivery [1-3] has gained significant attention and 
momentum since it offers remarkable advantages. Over past few 
decades, buccal route for systemic drug delivery using 
mucoadhesive polymers to significantly improve the performance of 
many drugs has been of profound interest. Administration of 
compounds via the mucosa of the oral cavity avoids pre-systemic 
metabolism in the gastrointestinal (GI) tract and hepatic first pass 
elimination. In addition, the buccal mucosa is a well-vascularised 
tissue and is easily accessible for both application and removal of a 
delivery device. It’s having facility to include permeation 
enhancer/enzyme inhibitor or pH-modifier in the formulation and 
versatility in designing as multidirectional or unidirectional release 
systems for local or systemic action, etc. Buccal drug delivery 
systems is a promising area for continued research with the aim of 
systemic delivery of orally inefficient drugs as well as a feasible and 
attractive alternative for non-invasive delivery of potent peptide and 
protein drug molecules. 
Nitroglycerin[4-5]is a vasodilator used in treatment of angina. It is 
well absorbed from the oral cavity and has low molecular weight, 
which favours its administration through buccal route.  
The objective of this research was to formulate and evaluate 
mucoadhesive buccal tablet containing nitroglycerin to prolong 
therapeutic effect, increase bioavailability of the drug and reduce the 
dosing frequency.In the present investigation mucoadhesive 
polymers [6-7] like Carbopol 934p, HPMC K4M, HPMC K15M and 
Sodium alginate were used to prepare mucoadhesive buccal tablets 
by employing direct compression technique. The prepared buccal 
tablets are subjected to evaluated for physicochemical properties 
and release characteristics 
MATERIALS AND METHODS 
Nitroglycerin was obtained as gift sample from Shasun 
pharmaceuticals Ltd, Pondicherry. Carbopol 934, Sodium alginate, 
Lactose and Talc were purchased from S.D. Fine – Chem. Ltd, 
Mumbai. HPMC K4M and HPMC K15M were purchased from 
Colorcon Asia Pvt. Ltd, Goa. The chemical reagents used were of 
analytical grade. 
Drug – Excipient compatibility studies 
Drug – Excipient compatibility study by Thin Layer 
Chromatography 
In this method drug and excipients in 1:2 ratio were mixed and 
analyzed for compatibility by using TLC after one, two, three and 
four weeks. 10µl of reference and test solutions were applied as 
spots on the dry activated plate. The solvent system was allowed to 
run up to desired height; the plates were removed and allowed to 
dry. The dry plates were then exposed to iodine vapors in a chamber 
to observe the spots. The plates were then removed and the Rƒ
Drug – Excipient compatibility study by Fourier Transform 
Infrared Spectroscopy (FTIR) 
 
values calculated. The details of chromatographic conditions were 
shown in Table no. 1. 
The pure drug and optimized formulations were subjected for FTIR 
analysis. The samples were scanned over a range of 4000-400 cm-1 
using Fourier transformer infrared spectrophotometer. Spectra’s 
were analyzed for drug polymer interactions. 
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Formulation of mucoadhesive buccal tablets 
Direct compression[8] method was employed to prepare buccal 
tablets of Nitro-glycerine using Carbopol 934p, HPMC K15M, HPMC 
K4M and Sodium alginate as polymers. Carbopol 934 is used as 
primary polymer due to its good mucoadhesive property. All the 
ingredients including drug, polymer and excipients were weighed 
accurately according to the batch formula and were passed through 
sieve no 40 to get uniform particle size.  
The drug and all the ingredients except lubricants were taken on a 
butter paper with the help of a stainless steel spatula and the 
ingredients were mixed in the order of ascending weights and 
blended for 10 min in an inflated polyethylene pouch. After uniform 
mixing of ingredients, lubricant was added and again mixed for 2 
min. The prepared blend of each formulation was compressed by 
using 8mm punch on a tablet punching machine. The formulation 
details are shown in Table no 2. 
 
Table 1: Details of Chromatographic Conditions 
Stationary phase Thin plates of Silica gel G having thickness of 0.25cm and activated at 110ºC for 30min prior to use 
Mobile phase Chloroform: Methanol (9:1) 
Separation technique Ascending 
Reference solution 5mg of Nitroglycerin was shaken with 5ml of mobile phase, decanted and used for spotting 
Test solution Drug-Excipient mixture equivalent to 5mg of Nitroglycerin was shaken with 5ml of mobile phase, decanted and used for 
spotting. 
 
Table 2: Composition of Nitroglycerin buccal tablets 
S. No. Ingredients Formulations 
Batch A* Batch B** Batch C*** 
A1 A2 A3 B1 B2 B3 C1 C2 C3 
1. Nitroglycerin 10 10 10 10 10 10 10 10 10 
2. Carbopol 934p 25 30 40 35 40 45 35 40 45 
3. HPMC K4M 45 40 30 -- -- -- -- -- -- 
4. HPMC K15M -- -- -- 35 30 25 -- -- -- 
5. Sodium alginate -- -- -- -- -- -- 35 30 25 
6. Lactose 18 18 18 18 18 18 18 18 18 
7. Talc 2 2 2 2 2 2 2 2 2 
*HPMC K4M, **HPMC K15M and ***Sodium alginate used as a secondary polymer. 
 
Evaluation of mucoadhesive buccal tablets 
Evaluation was performed to assess the physicochemical properties 
and release characteristics of the developed formulations. 
Pre-compression parameters [9] 
Angle of Repose  
Angle of repose is defined as the maximum angle possible between 
the surface of the pile of the powder and the horizontal plane. The 
flow characteristics of different microcapsules were studied by 
measuring the angle of repose employing fixed funnel method. The 
angle of repose was calculated by using the following formula.  
pile  theof base  theof radius
pile  theofHeight   Tan =θ
 
where θ = tan-1 (h / r) θ = angle of repose.  
Bulk Density & Tapped Density  
Bulk density and tapped density were measured by using 10 ml of 
graduated cylinder. The pre weighed sample was placed in a 
cylinder; its initial volume was recorded (bulk volume) and 
subjected to tapings for 100 times.  
Then the final volume (tapped volume) was noted down. Bulk 
density and tapped density were calculated from the following 
formula. 
ebulk volum
clesmicroparti of mass DensityBulk  =
 
 volumetapped
clesmicroparti of mass Density Tapped =
 
Carr’s Index s 
Compressibility index (CI) or Carr’s index value of microparticles 




densityBulk  -density  Tapped  (%)Index  sCarr' =
 
Hausner’s Ratio  
Hausner ratio of microspheres was determined by comparing the 
tapped density to the bulk density using the equation: 
densityBulk 
density Tapped Ratio sHausner' =
 
Post compression parameters [10] 
Tablet thickness and diameter 
Thickness and diameter of tablets were important for uniformity of 
tablet size. Thickness and diameter were measured using Vernier 
calipers. 
Hardness 
This test is used to check the hardness of a tablet which may 
undergo chipping or breakage during storage, transportation and 
handling. In this five tablets were selected at random and the 
hardness of each tablet was measured with Monsanto hardness 
tester. The hardness is usually measured in terms of kg/cm2
Uniformity of weight 
.  
This test is performed to maintain the uniformity of weight of each 
tablet which should be in the prescribed range, this is done by 
sampling and weighing 20 tablets at random and average weight is 
calculated.  
Friability test 
The friability of tablets was determined using Roche friabilator. It is 
expressed in percentage (%). Ten tablets were initially weighed 
(Winitial) and transferred into friabilator. The friabilator was 
operated at 25rpm for 4 min or run up to 100 revolutions. The 
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tablets were weighed again (Wfinal
Content uniformity 
). The % friability was then 
calculated by –  




Tablet containing 10mg of drug is dissolved in 100ml of pH 6.4 
saline phosphate buffer taken in volumetric flask. The drug is 
allowed to dissolve in the solvent. The solution was filtered, 1ml of 
filtrate was taken in 100ml volumetric flask and diluted to mark 
with pH 6.4 saline phosphate buffer and analyzed spectroscopically 
at 210nm. The concentration of Nitroglycerin in mg/ml was 
obtained by using standard calibration curve of the drug. Drug 
content studies were carried out in triplicate for each formulation 
batch. 
Swelling studies [11] 
Buccal tablets from each batch were individually weighed (W1) and 
placed separately in each petri dish with 15 ml of phosphate buffer 
(pH 6.4 saline phosphate buffer). At time intervals of 1, 2, 3, 4, 5, 6, 7 
and 8, the tablet was removed from each Petri dish and excess 
surface water from the tablet was wiped out carefully with filter 
paper. Each swollen tablet was reweighed (W2) and the swelling 
index (SI) was calculated using the following formula 






= Initial weight of the tablet, 
2
Mucoadhesion strength [12] 
= Weight of the tablet after specific time interval. 
Mucoadhesion strength of the tablet was measured on a modified 
physical balance (fig.6) employing the method as described by Gupta 
et al using sheep buccal mucosa as model mucosal membrane. Fresh 
sheep buccal mucosa was obtained from a local slaughter house and 
was used within 2 hrs of slaughtering. The mucosal membrane was 
washed with distilled water and then with phosphate buffer pH 6.8. 
A double beam physical balance was taken and to the left arm of 
balance a thick thread of suitable length was hanged and to the 
bottom side of thread a glass stopper with uniform surface was tied. 
The buccal mucosa was tied tightly with mucosal side upward using 
thread over the base of inverted 50 ml glass beaker which was 
placed in a 500 ml beaker filled with phosphate buffer pH 6.8 kept at 
37o
The buccal tablet was then stuck to glass stopper from one side 
membrane using an adhesive (Feviquick). The two sides of the 
balance were made equal before the study, by keeping a weight on 
the right hand pan. A weight of 5 g was removed from the right hand 
pan, which lowered the glass stopper along with the tablet over the 
mucosal membrane with a weight of 5 g. The balance was kept in 
this position for 3 min. Then, the weights were increased on the 
right pan until tablet just separated from mucosal membrane. The 
excess weight on the right pan i.e. total weight minus 5gm was taken 
as a measure of the mucoadhesive strength.  
 C such that the buffer reaches the surface of mucosal membrane 
and keeps it moist.  
The mean value of three trials was taken for each set of 
formulations. After each measurement, the tissue was gently and 
thoroughly washed with phosphate buffer and left for 5 minutes 
before placing a new tablet to get appropriate results for the 
formulation. After calculating mucoadhesion strength the force of 
adhesion and bond strength parameters were calculated from 
following equations as;  
Force of Adhesion (N) = Mucoadhesive strength × 9.8 / 1000 
Bond Strength (N/m2
Surface pH study [13] 
) = Force of Adhesion / Surface Area. 
The surface pH of the buccal tablets was determined in order to 
investigate the possibility of any side effects in-vivo. As the acidic or 
alkaline pH may cause irritation to the buccal mucosa, the pH was 
maintained to neutral as closely as possible. A combined glass 
electrode was used for this purpose. The tablet was allowed to swell 
by keeping it in contact with 1 ml of distilled water (pH 6.4 ± 0.05) 
for 2 hrs at room temperature. The pH was measured bringing the 
electrode in contact with the surface of the tablet and allowing it to 
equilibrate for 1 min. 
Ex vivo drug permeation [14] 
Ex vivo drug permeation through the sheep buccal mucosa was 
performed using modified Franz diffusion cell at 37±0.5°C. The 
freshly cut sheep buccal mucosa after removing underlying fat and 
loose tissues and washing with phosphate buffer pH 6.4 and distilled 
water was mounted between the donor and receptor compartments. 
The receptor compartment (16 ml capacity) was filled with 
phosphate buffer pH 7.4, and the buccal mucosa was allowed to 
stabilize for 30 min by hydrodynamics in the receptor compartment 
by stirring on a magnetic stirrer at 50 rpm and was maintained for 
the entire study. A 1 ml aliquot was withdrawn at predetermined 
time intervals and replaced with fresh medium. The aliquots were 
analyzed after appropriate dilution by UV spectrophotometer 
(Systronics 117) at 210 nm.  
Ex vivomucoadhesion time [15]  
The mucoadhesive performance of the buccal tablets was evaluated 
using Fresh sheep buccal mucosa obtained from local slaughter 
house. The ex vivo mucoadhesion time was performed after 
application of the buccal tablet on freshly cut sheep buccal mucosa. 
The fresh sheep buccal mucosa was tied on the glass slide and a 
buccal tablet was wetted with 1 drop of phosphate buffer pH 6.8 and 
pasted to the sheep buccal mucosa by applying a light force with a 
fingertip for 30 sec. The glass slide was then put in the beaker, which 
was filled with 200 ml of the phosphate buffer pH 6.8 and was kept 
at 37 ± 1°C. After 2 min, a 50 rpm stirring rate was applied to 
simulate the buccal cavity environment and tablet adhesion was 
monitored for 12 hrs. The time for the tablet to detach from the 
sheep buccal mucosa was recorded as the mucoadhesion time. 
In vitro dissolution studies [16] 
In vitro release studies were carried out using USP dissolution 
testing apparatus II (paddle type). The dissolution medium 
consisted of 500 ml of saline phosphate buffer (pH 6.4). The release 
was performed at 37ºC ±.5ºC, with a rotation speed of 50 rpm. 
Samples (5ml) were withdrawn at predetermined time intervals (1, 
2, 3 up to 8 hrs) and volume was replaced with the fresh medium. 
The samples were filtered through Whatman filter paper and 
analyzed after appropriate dilution by UV spectrophotometer at 
210nm. The experiments for different Batches A, B and C 
formulations were conducted in triplicate and average values were 
recorded. The release kinetics such as zero order, first order, 
Higuchi and Hixson- Crowell were determined. 
Drug release kinetics [17-18] 
To analyze the mechanism of release and release rate kinetics of the 
dosage form, the data obtained were fitted into Zero order, First 
order, Higuchi matrix, Peppas and Hixson-Crowell model using PCP-
DISSO-v3 software. Based on the r-value, the best-fit model was 
selected. To study the release kinetics, data obtained from in vitro 
drug release studies were plotted as log cumulative percentage drug 
release versus log time. 
Stability studies 
In the present study, stability studies were carried out at 400
RESULTS AND DISCUSSION 
C and 
75% RH for a specific time period up to 4 weeks for optimized 
formulation. For stability study, the tablets were sealed in 
aluminium packaging coated inside with polyethylene. These sample 
containers were placed in desiccator maintained at 75% RH. The 
samples were analyzed for the following parameters like surface pH, 
hardness and drug content. 
Drug – Excipient compatibility study by TLC 
Pavan et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 7, 251-259 
 
254 
This study confirmed no interaction between the drug and 
excipients i.e., the physical appearance of drug-excipient mixture, Rƒ 
valueand λmax 
 
of drug observed for 4 weeks were found to be almost 
similar with the initial observations. Hence, it can be concluded that 
the drug Nitroglycerin was found to be compatible with the 
excipients used in the designed formulation. The observations of 
drug-excipient compatibility study were tabulated in Table 3 and 4.
Table 3: Observations of Drug-Excipient study by TLC 
Ingredients Observations at 0 day 
Appearance R λƒ max (nm) 
Drug White 0.315 210 
Drug ± HPMC K4M White 0.312 210 
Drug ± HPMC K15M White 0.314 210 
Drug ± Carbopol 934p White 0.313 210 
Drug ± Sodium alginate White creamy 0.316 210 
Drug ± Lactose White 0.315 210 
 
Table 4: Observations of Drug-Excipient study by TLC at 1st, 2nd, 3rd and 4th
Ingredients 
 week. 
1st 2 week nd 3 week rd 4 week th week 
A R λƒ A max R λƒ A max R λƒ A max R λƒ max 




NC 0.314 NC NC 0.314 NC NC 0.312 NC NC 0.315 NC 
Drug 
+ 
HPMC K 15M 












NC 0.314 NC NC 0.317 NC NC 0.314 NC NC 0.313 NC 
A = Appearance, NC = No change. 
 
Drug – Excipient compatibility study by FTIR study:  
Based on the FTIR interpretation results, all the major drug peaks 
were identified when compared with the physical mixture of drug 
and polymer, which ensures that there was no any chemical 
interaction between them. The major sharp and significant peaks 
(functional groups) of the drug and drug and polymer mixture are 
shown in Table No.5 and the spectra are shown in Figure No 1, 2, 3, 
and 4. 
 
Fig. 1: FTIR spectra of pure Nitroglycerin. 
 
Pre-compression parameters: The angle of repose values were 
found to be in the range from 23.37º to 27.15º. This indicates good 
flow property of the blend.The values of bulk density were found to 
be in the range from 0.255gm/cm3 to 0.317gm/cm3 and tapped 
density from 0.312gm/cm3 to 0.380gm/cm3
 
. Compressibility index 
value ranges between 15.06% to 19.44% indicating that the powder 
blend have the required flow property for direct compression.The 
values of Hausner’s ratio were found to be in range 1.177 to 1.24. 
The details of pre-compression parameters are tabulated in Table 
No. 6. 
Fig. 2: FTIR spectra of A batch. 
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Post-compression parameters: Tablets mean thickness were 
almost uniform in all the formulations and were found to be in the 
range of 1.57mm to 1.61mm.  
 
Fig. 3: FTIR spectra of B batch 
The measured hardness of tablets of each batch ranged between 
4.5kg/cm2 to 5.2kg/cm2
The % friability was less than 1% in all formulations ensuring that 
the tablets were mechanically stable.The percentage of drug content 
was in the range of 96.13% to 99.67% and found to be within 
acceptable limits. The details of post compression parameters are 
shown in Table No. 7. 
. This ensures good handling characteristics 
of all batches.All the tablets passed weight variation test as the % 
weight variation was within the pharmacopoeial limits of ±10% of 
the weight. The weights of all the tablets were found to be uniform 
with low standard deviation. 
 
Fig. 4: FTIR spectra of C batch
 
Table 5: FTIR Spectral Interpretation of pure drug and formulations 
S. No. Ingredients Functional groups 
C-O(Str) N=O (Str) C-H (Str) CH (Df) 
1. Drug 1276.53 1654.61 2899.77 1358.37 
2. Drug +HPMC K4M 1233.91 1661.37 2865.66 1378.30 
3. Drug + HPMC K15M 1274.27 1655.37 2834.56 1337.84 
4. Drug + Carbopol 934p 1270.05 1656.60 2836.45 1376.22 
5. Drug + Sodium Alginate 1274.46 1658.23 2853.30 1350.50 
6. Drug + Lactose 1275.87 1654.63 2898.56 1352.56 
7. Drug + All excipients(A) 1225.54 1682.91 2907.74 1350.31 
8. Drug + All excipients(B) 1247.67 1634.07 2848.91 1346.09 
9. Drug + All excipients(C) 1243.55 1654.62 2847.45 1350.99 
 
Table 6:Pre-compression parameters of powder blend 







A1 24.65±0.020º 0.266±0.028 0.326±0.026 18.40±0.021 1.225 
A2 25.76±0.021º  0.261±0.023 0.324±0.030 19.44±0.030 1.241 
A3 24.98±0.015º 0.255±0.011 0.312±0.028 18.26±0.027 1.223 
B1 25.19±0.020º 0.278±0.025 0.340±0.032 18.32±0.036 1.223 
B2 27.15±0.038º 0.270±0.026 0.335±0.036 19.40±0.019 1.240 
B3 26.85±0.018º 0.276±0.015 0.333±0.016 17.11±0.026 1.206 
C1 26.64±0.038º 0.317±0.026 0.380±0.022 16.57±0.019 1.198 
C2 23.37±0.038º 0.310±0.016 0.369±0.015 15.98±0.023 1.190 
C3 24.75±0.038º 0.310±0.029 0.365±0.026 15.06±0.013 1.177 
 
Table 7: Post-compression parameters of Nitroglycerin buccal tablets 








A1 0.101±0.005 4.55±0.05 1.58±0.02 0.74±0.04 98.72 
A2 0.102±0.006 4.79±0.04 1.59±0.04 0.72±0.06 97.78 
A3 0.100±0.005 4.82±0.03 1.60±0.05 0.45±0.02 97.07 
B1 0.102±0.004 4.90±0.06 1.59±0.03 0.56±0.04 96.13 
B2 0.100±0.005 5.10±0.05 1.61±0.04 0.61±0.07 99.67 
B3 0.101±0.005 5.15±0.05 1.59±0.04 0.76±0.04 97.59 
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C1 0.102±0.005 4.85±0.05 1.60±0.04 0.65±0.04 98.15 
C2 0.100±0.005 4.95±0.05 1.57±0.04 0.63±0.04 96.85 
C3 0.101±0.005 4.97±0.05 1.58±0.04 0.68±0.04 97.78 
 
Swelling studies 
The swelling of all the tablets was increased as the time proceeds 
because the polymer gradually absorbs water due to hydrophilicity 
of the polymer. The outermost hydrophilic polymer layer 
hydrates/swells first and as the hydrated layer progressively 
dissolves or disperse, the hydration swelling process will continuous 
towards new expose surfaces thus maintaining the integrity of 
dosage form. The swelling index was 182.844 to 193.654 for the 
formulation Batch A which contains Carbopol 934 as primary 
polymer and HPMC K4M as secondary polymer. The swelling index 
was 203.119 to 213.356 for the formulation Batch B which contains 
Carbopol 934 as primary polymer and HPMC K15M as secondary 
polymer.  The swelling indices of the tablets with Carbopol 934 P 
and HPMC increased with increasing amounts of Carbopol 934 P. It 
was observed that when tablet came in contact with aqueous 
medium, wetting occurred first at the lower surface of tablet and 
then progressed to whole. The rate of spreading of water was 
dependent on the ratio of two polymers used. The swelling was 
getting affected in the formulations containing secondary polymer 
along with Carbopol as a primary polymer. The highest swelling was 
283.458 to 299.851 for formulations Batch C which contains sodium 
alginate as secondary polymer because sodium alginate is more 
water soluble and rapidly get hydrated. The swelling index was 
affected by the increasing the concentration of Carbopol 934 as 
represented in fig 5.  
 




The tablets with the HPMC K4M have bioadhesive strength in 
between the 22.33 gm to 26.26 gm. The tablets with the HPMC K15M 
have bioadhesive strength in between the 23.68 gm to 25.59 gm. The 
tablets with the Sodium alginate have bioadhesive strength 21.87 
gm to 24.89 gm. Carbopol 934 is selected as primary polymer 
because of its good mucoadhesive property. Results indicate that by 
increasing concentration of Carbopol 934, the mucoadhesive 
strength increases. The results are illustrated in Figure 6. 
 
Fig. 6: Mucoadhesive strength and Surface pH profile of all three 
batches A, B and C formulations 
Surface pH 
The maximum surface pH of all the formulation was found to be 6.75 
and the minimum was 6.48. The results reveal that all the 
formulations provide an acceptable pH in the range of 5.5 to 7.0 
(salivary pH). Hence, they may not produce any local irritation to the 
mucosal. The results are illustrated in Figure 6. 
Ex vivo permeation studies: 
The optimized formulation C3 which showed 75.39% of in vitro drug 
release in 8 hrs is selected for performing ex vivo permeation studies 
by using sheep buccal mucosa. The results are shown in Table 8.  
 
Table 8: Permeation study profile of C3 formulation 
S. No. Time in hrs Cumulative amount 
released ± S.D 
1 1 2.800 ±0.007 
2 2 5.760 ±0.008 
3 3 11.354 ±0.014 
4 4 15.702 ±0.014 
5 5 20.785 ±0.029 
6 6 26.626 ±0.029 
7 7 32.376 ±0.024 
8 8 38.297 ±0.023 
 
Ex vivo mucoadhesive time 
The Batch C formulations which are showing controlled drug release 
for 8 hrs are selected for performing mucoadhesive residence time. 
The ex-vivo mucoadhesion time was examined after application of 
the buccal tablet on sheep buccal mucosa. The result showed in 
Table No. 9, revealed that the mean adhesion time was promising in 
the batch Cformulations containing Carbopol 934 and sodium 
alginate. This may be due to the flexibility of Carbopol 934, which 
easily diffuses and interpenetrates into the mucin and get entangled 
with that of mucin. The mucoadhesive time on sheep buccal mucosa 
ranged from 10.46±0.040 to 12.26±0.010 hours.  
 
Table 9: Ex vivo Residence time of Batch C formulations 
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Fig. 7: In vitro dissolution study of Batch-A formulations 
 
In vitro release study 
The in vitro release of Nitroglycerin was mainly affected by drug 
polymer ratio, nature and amount of polymer and the dissolution 
medium. The buccal tablets of Batch A containing Nitroglycerin with 
primary polymer Carbopol 934 and secondary polymer HPMC K4M 
showed initially a rapid burst release of the drug 94.31%, 96.78% 
and 97.03% for 2½, 3 and 4hrs respectively. The buccal tablets of 
Batch B containing HPMC K15M as secondary polymer showed drug 
release of 96.90%, 90.21% and 85.74% for 5hrs.  
 
 
Fig. 8: In vitro dissolution study of Batch-B formulations. 
 
The buccal tablets of Batch C containing sodium alginate as 
secondary polymer showed drug release of 91.31%, 86.55% and 
75.39% for 8 hrs. Among the secondary polymers used, sodium 
alginate showed extended drug release up to 8 hrs.  
 
Formulation C3 which is showing 75.39% drug release in 8 hrs is 
selected as optimized formulation. The increase in concentration of 
Carbopol in all tablet formulations significantly affects the release of 
drug. The in vitro release profiles are shown in Fig No. 7, 8 and 9. 
 
 
Fig. 9: In vitro dissolution study of Batch-C formulations 
 
Drug release kinetics 
The results of dissolution data were fitted to various kinetic 
equations to analyze the release mechanism. All the formulations of 
batch C & A except A1 followed zero order kinetics and all other 








The ‘n’ value of all the formulations was found to be more than 0.89 
indicating that the drug release followed Super case II transport type 
of release mechanism due to the erosion of the polymer.  
But the formulation B1 showed the ‘n’ value 0.69 indicating that the 
drug release occurred via non-fickian diffusion. The kinetic plots 
obtained of respective batches are shown in Fig 10, 11 and 12. 
Stability studies 




C/75% RH for 30 days. The results of stability studies revealed 
no change in Surface pH, hardness, in-vitro drug release and drug 
content indicating the formulation was stable. The values are 
tabulated in Table11. 










0 6.58 4.95 75.39 99.72 
1 6.62 4.95 74.56 99.55 
2 6.58 4.93 77.63 99.21 
3 6.60 4.92 75.74 98.96 
4 6.62 4.92 73.87 98.71 
 
Fig. 11: release kinetic plots for formulation B. 
 
Fig. 12: release kinetic plots for formulation C 
Pavan et al. 





The mucoadhesive buccal tablets of Nitroglycerin could be prepared 
using Carbopol 934 as primary polymer in combination of secondary 
polymers like HPMC K4M, HPMC K15M and sodium alginate by 
direct compression method. All the prepared tablets were in 
acceptable range of weight variation, hardness, thickness, friability 
and drug content as per pharmacopoeial specification. The increase in 
concentration of Carbopol can increase hardness.The surface pH of 
prepared buccal tablets was in the range of salivary pH, suggested that 
prepared tablets could be used without risk of mucosal irritation. 
The buccal tablets showed good swelling up to 8 hrs in pH 6.4 saline 
phosphate buffer maintaining the integrity of formulation which is 
required for bioadhesion. The increase in Carbopol concentration 
significantly increased the swelling. Buccal tablets containing 
sodium alginate as secondary polymer showed better swelling 
index.The in vitro release of Nitroglycerin was extended 4-5 hrs, if 
Carbopol used in combination with secondary polymers like HPMC 
K4M and HPMC K15M. While the tablets contained Carbopol along 
with sodium alginate could be used to prepared prolonged released 
buccal tablet.  
The in vitro release obeyed zero order kinetics with mechanism of 
release was erosion followed by non-fickian diffusion due to more 
hydrophilic nature of polymer. The increase in concentration of 
Carbopol significantly affects the in vitro release of Nitroglycerin. 
Although all formulations of Batch C exhibited satisfactory drug 
release, formulation C3 is considered as optimized formulation as it 
is able to release complete drug for 12 hrs.All the tablets of Batch C 
prepared using sodium alginate as secondary polymer showed good 
mucoadhesive residence time of 10.46±0.040 to 12.26±0.010 hrs 
indicated good adhesive capacity of polymers used. All the tablets 
showed good mucoadhesive strength of 21.87 to 26.26 with high 
force of adhesion. The mucoadhesive strength was increased by 
increasing the concentration of Carbopol 934 as it is having good 
mucoadhesive property.In vitro diffusion studies of the optimized 
formulation C3 revealed that percent drug permeated through sheep 
buccal mucosa was 38.294 % for 8 hrs. The slopes of the basic in 
vitro data suggests that drug permeates across the membrane but 
slowly as the mucosa offers barrier to the transportation of the drug. 
Stability studies were conducted according to ICH guidelines region 
IV at 400
Declared None 
C / 75 % RH indicates that there is no decrease in drug 
content, surface pH or no significant difference between the means 
of profiles without stress and with stress at p<0.05 observed for a 
period of 4 weeks.  Based on the results obtained so far, it was 
concluded that the objectives of the investigation was fulfilled. 
Hence, the mucoadhesive buccal tablets of Nitroglycerin can be 
prepared with enhanced bioavailability and prolonged therapeutic 
effect for the prevention of angina attacks. The study conducted so 
far reveals a promising result suggesting scope for 
pharmacodynamic and pharmacokinetic evaluation.  
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